{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'TABLE OF CONTENTS', 'PAGE', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', '3', '1. SYNOPSIS', '10', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', '17', '3.', 'INTRODUCTION', '19', '3.1.', 'Study Rationale', '19', '3.2.', 'Background', '21', '3.3.', 'Benefit/Risk Assessment', '23', '3.3.1.', 'Risk Assessment', '24', '3.3.2.', 'Risk Assessment for Tiotropium Bromide 18 mcg', '35', '3.3.3.', 'Benefit Assessment', '35', '3.3.4.', 'Overall Benefit:Risk Conclusion', '36', '4.', 'OBJECTIVES AND ENDPOINTS', '37', '5.', 'STUDY DESIGN', '38', '5.1.', 'Overall Design', '38', '5.2.', 'Number of Participants', '40', '5.3.', 'Participant and Study Completion', '40', '5.4.', 'Scientific Rationale for Study Design', '40', '5.5.', 'Dose Justification', '41', '6.', 'STUDY POPULATION', '41', '6.1.', 'Inclusion Criteria', '41', '6.2.', 'Exclusion Criteria', '42', '6.3.', 'Randomisation Criteria', '47', '6.4.', 'Lifestyle Restrictions', '47', '6.5.', 'Pre-screening/Screening/Run-in/Randomisation Failures', '47', '7. TREATMENTS', '48', '7.1.', 'Treatment Groups and Duration', '48', '7.1.1.', 'Medical Devices', '51', '7.2.', 'Dose Modification', '51', '7.3.', 'Method of Treatment Assignment', '51', '7.4.', 'Blinding', '51', '7.5.', 'Preparation/Handling/Storage/Accountability', '52', '7.6.', 'Treatment Compliance', '53', '7.7.', 'Concomitant Therapy', '53', '7.7.1.', 'Permitted Medications and Non-Drug Therapies', '53', '7.7.1.1.', 'Permitted COPD Medications', '53', '7.7.1.2.', 'Permitted Non-COPD Medications', '54', '7.7.2.', 'Prohibited Medications and Non-Drug Therapies', '55', '7.8.', 'Treatment after the End of the Study', '57', '8.', 'DISCONTINUATION CRITERIA', '57', '8.1.', 'Discontinuation of Study Treatment', '57', '8.1.1.', 'Rechallenge', '59', '7']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '8.1.1.1.', 'Study Treatment Restart or Rechallenge', '59', '8.2.', 'Withdrawal from the Study', '59', '8.3.', 'Lost to Follow Up', '59', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', '60', '9.1.', 'Efficacy Assessments', '61', '9.1.1.', 'Spirometry', '61', '9.1.1.1.', 'Reversibility', '62', '9.1.2.', 'SGRQ-C', '62', '9.1.3.', 'COPD Assessment Test (CAT)', '63', '9.1.4.', 'COPD Exacerbations', '63', '9.2.', 'Adverse Events', '63', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '64', '9.2.2.', 'Method of Detecting AEs and SAEs', '64', '9.2.3.', 'Follow-up of AEs and SAEs', '64', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', '65', '9.2.5.', 'Cardiovascular and Death Events', '65', '9.2.6.', 'Disease-Related Outcomes - COPD exacerbations', '65', '9.2.7.', 'COPD exacerbations should not be recorded as an', 'adverse event, unless they meet the definition of an SAE', '(Appendix 6) Pneumonia', '66', '9.2.8.', 'Sentinel Events', '66', '9.2.9.', 'Pregnancy', '67', '9.2.10.', 'Medical Device Incidents (Including Malfunctions)', '67', '9.2.10.1. Time Period for Detecting Medical Device', 'Incidents', '67', '9.2.10.2. Follow-up of Medical Device Incidents', '67', '9.2.10.3.', 'Prompt Reporting of Medical Device Incidents', 'to Sponsor', '68', '9.2.10.4.', 'Regulatory Reporting Requirements for', 'Medical Device Incidents', '68', '9.3.', 'Treatment of Overdose', '68', '9.4.', 'Safety Assessments', '68', '9.4.1.', 'Physical Examinations', '69', '9.4.2.', 'Vital Signs', '69', '9.4.3.', 'Electrocardiograms', '69', '9.4.4.', 'Clinical Safety Laboratory Assessments', '69', '9.5.', 'Pharmacokinetics', '70', '9.6.', 'Pharmacodynamics', '70', '9.7.', 'Genetics', '70', '9.8.', 'Biomarkers', '70', '9.9.', 'Medical Resource Utilization and Health Economics', '70', '9.10.', 'Smoking Cessation Counselling', '70', '10. STATISTICAL CONSIDERATIONS', '71', '10.1. Hypotheses', '71', '10.2. Sample Size Determination', '71', '10.3.', 'Populations for Analyses', '71', '10.4.', 'Statistical Analyses', '72', '10.4.1.', 'Efficacy Analyses', '72', '10.4.2.', 'Safety Analyses', '73', '8']\n\n###\n\n", "completion": "END"}